WHO is about to put the Russian vaccine as the second emergency vaccine

WHO is about to put the Russian vaccine as the second emergency vaccine


(News 24h) – Russia will consult WHO in late January to bring the COVID-19 Sputnik V vaccine to emergency.

The Russian news agency TASS quoted Sergei Glagolev, an adviser to the Russian Health Minister, as saying that the Russian side is conducting consultations with the World Health Organization (WHO) experts regarding the use of Sputnik vaccine. V in emergency situations.

WHO has recently launched the Russian vaccine as a second-hand vaccine
The WHO could soon put the Russian vaccine on the emergency program.

The consultations will be held at the end of January 2021, according to Mr. Glagolev.

“The first consultation with WHO experts on licensing requirements for Sputnik V vaccines in emergency situations will be held online after January 20,” he said in an interview. with the Rossiya-1 TV channel.

Earlier, Assistant Minister of Health of Russia Alexey Kuznetsov said that WHO’s inclusion of Sputnik V in the list of vaccines used in emergency situations will help simplify the registration of the vaccine abroad, while opening up Vaccine supply opportunities within the framework of international drug supply programs under the auspices of the United Nations (UN), such as through WHO and UNESCO.

The best defense against infectious diseases is vaccination, and pandemic COVID-19 is no exception.

The Russian Direct Investment Fund (RDIF) said that more than 1.5 million people worldwide have been vaccinated against COVID-19 with the Sputnik V vaccine.

Algeria becomes the first African country to license the use of Russia’s Sputnik V vaccine. Algeria’s Ministry of Pharmaceutical Industry on 10/1 licensed the emergency use of Sputnik V vaccine.

A press release released by the ministry said that the Ministry’s National Drug Administration has licensed Sputnik V under an executive order on emergency measures to conduct a vaccine campaign in the country.

This makes Algeria the first country on the African continent to register the vaccine.

Sputnik V uses two different vectors for the two vaccinations, providing immunity for a longer duration than vaccines that use the same delivery mechanism for both vaccines, according to the vaccine’s official website. two injections ”.

“The price of the Sputnik V vaccine is less than $ 10 per injection, making it affordable around the world” – the statement stated.

The Sputnik V vaccine has also been approved in Belarus, Serbia, Argentina, and Bolivia and the EU vaccine approval process has begun.

In Russia, Sputnik V has been allowed to use for people over 60 years old. Russian Minister of Health Mikhail Murashko announced that the monitoring and inspection during the past time shows the safety and effectiveness of the drug.

“This vaccine has been approved for use in people 18 years of age and older and do not suffer from chronic diseases. People over 60 years old can also be vaccinated with COVID-19 with this vaccine” – Mr. Murashko said. .

The United States moves towards a second dose of COVID-19 vaccine

On January 10, the US started to inject the second dose of Covid-19 vaccine for the group that received the first shot 21 days ago, increasing the vaccine efficacy by 95%.

Deploying the second dose has the same logistical problems associated with the first injection, including vaccine storage and safety. In addition, health facilities must ensure adequate vaccines, on time, and with the right people who received the first dose.

WHO has recently launched the Russian vaccine as a second-hand vaccine
Bracelets for participants in Covid-19 vaccination during the second round of PeaceHealth Health System. Photo: NPR

Ensuring enough doses of the vaccine and vaccinating everyone is still in phase 1A.

“The problems that arise are really unpredictable in the vaccine delivery process,” said Maryellen Guinan, the America’s Essential Hospitals Association, which represents more than 300 public hospitals in the US.

To date, the US has not reported any serious problems related to the missed second dose. However, experts say it is still too early to take the problem lightly, the feasibility of mass deployment of the second nose will be tested in the coming weeks.

The Centers for Disease Control and Prevention (CDC) statistics 6.6 million Americans who received the first dose. There are no nationwide data on second-shot completion rates.

The PeaceHealth Center operates clinics and hospitals throughout the Northwestern United States, and now vaccines about 3,000 workers in Washington. No serious problems have been reported, hospital chief executive Charles Prosper said.

In early January, PeaceHealth had a second dose of vaccine short for two days. However, before that, the system had reserved enough doses to promptly replace the delayed shipment.

Huy Vu

.

Related Posts